IRCT20190217042735N1RecruitingPhase 3
The comparison between Olanzapine- Aprepitant- Granisetron effects on chemotherapeutic drug induced nausea and vomiting in patients
Zahedan University of Medical Sciences0 sites105 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 3
- Status
- Recruiting
- Sponsor
- Enrollment
- 105
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 18 years to 65 years (—)
- Sex
- All
Inclusion Criteria
- •Informed consent
- •Receiving chemotherapy regimens with moderate and high nausea and vomiting
- •Serum Creatinine 2 or less
- •AST and ALT less than 3 times of normal upper limit
- •Absolute Neutrophil counts of more than 1500 cubic millimeters
- •Not having another cause for nausea and vomiting, such as brain tumors and stomach cancer
Exclusion Criteria
- •Having nausea and vomiting too much and uncontrollable
- •Having allergies or showing other side effects of medications
- •Pregnant and lactating women
- •Having chronic illnesses such as: severe heart failure, uncontrolled diabetes, cardiac arrhythmia and cardiac infarction over the past 6 months
- •Use of other interventions or confusing drugs (Quinolones, abdominal radiotherapy, other underlying conditions, etc.)
- •Treatment with other antipsychotic drugs (Risperidone, Quetiapine, Clozapine, Phenothiazine) 30 days before entering the study
- •Having known problem in the CNS (cerebral metastasis or seizure) or cognitive impairment
- •Having nausea and vomiting 24 hours before treatment
Investigators
Similar Trials
Completed
Phase 3
Aprepitant and Olanzapine in the treatment of vomitingCTRI/2017/12/010869Mysore medical college ad research institute
Recruiting
Phase 3
Olanzapine versus Aprepitant in the triplet regimen for preventing highly emetogenic chemotherapy-induced nausea and vomiting: a double blind, non-inferiority, randomized phase 3 trialmalignant tumor(only solid tumor)JPRN-UMIN000034225Department of Surgery, Keio University School of Medicine130
Completed
Phase 2
The efficacy of combination of Olanzapine, Aprepitant, Palonosetron and dexamethasone for the prevention of nausea and vomiting in patients receiving autologous peripheral blood stem cell transplantation for multiple myelomamultiple myelomaJPRN-UMIN000035970Hitachi general hospital52
Completed
Not Applicable
Comparison of body weight, blood sugar level and lipid profile with atypical antipsychotics olanzapine versus iloperidoneCTRI/2014/10/005144Rohilkhand Medical College And Hospital100
Completed
Phase 2
Comparing the effect of adding Olanzapine versus Perphenazine on maintenance treatment of bipolar type I in outpatients referred to psychiatric clinic of Ahvaz Golestan Hospital in 2010Mania.Mania without psychotic symptomsIRCT201010315060N1Vice chancellor for Research, Ahvaz University of Medical science and Health Services40